Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:18 PM
Ignite Modification Date:
2025-12-24 @ 9:18 PM
NCT ID:
NCT02328404
Eligibility Criteria:
Inclusion Criteria:
* Female gender.
* Aged between 18 and 49 years old.
* Ethnic group (Caucasian, Middle-eastern).
* Overweight (BMI 25-30 kg\^m2).
* Diagnosed with Polycystic ovary syndrome according to Rotterdam criteria (Rotterdam SHRE-ASRM Sponsored Polycystic ovary syndrome consensus workshop group, 2004).
* Diagnosed with hypovitaminosis D (serum 25(OH)D level \< 20 ng/mL).
* Inadequate dietary intake of vitamin D (\<600 IU/day or \<15μg/day).
* Physical examination being assessed and accepted by the attending physician.
* Systolic blood pressure within the normal range (90-140 mmHg).
* Diastolic blood pressure within the normal range (60-90 mmHg).
* Heart rate within the normal range (60-100 BPM).
* Oral body temperature within the normal range (35.9 - 37.6 Cᵒ).
* Normal complete blood count , Liver Function enzymes test , Aspartate Transaminase (AST) , Alanine Transaminase (ALT) and Kidney function tests , Blood Urea Nitrogen (BUN) and Serum Creatinine (SrCr).
* Participant is willing and able to give informed consent for participation in the study.
* Able and willing to comply with all study requirements.
Exclusion Criteria:
* Female participants who are pregnant, lactating or planning pregnancy during the course of the study.
* Ethnic group: non Caucasian.
* Females aged \<18 or \>49 years old.
* Underweight, normal body weight ,Body Mass Index (BMI) \< 25 kg\^m2
* Obese or morbidly obese (BMI \> 30 kg/m2)
* Diagnosis with type 1 or type 2 diabetes mellitus, hypothyroidism, hyperthyroidism, liver disease, renal dysfunction, cardiovascular diseases, androgen-secreting tumor, Cushing syndrome, congenital adrenal hyperplasia, hyperprolactinemia, and/or virilism.
* Known history or presence of food allergies or intolerance (e.g dairy products or gluten-containing foods), or any known condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs.
* History of drug or alcohol abuse, smoking of 10 cigarettes or more (or equivalent) per day.
* Participants who took medications known to affect metabolic parameters, such as metformin and corticosteroid drugs, vitamin D and calcium.
* Adequate dietary intake of vitamin D (600 IU/day or 15μg/day or more).
* Participation in another clinical or bioequivalence study within 90 days prior to the start of this study period.
* Participants with abnormal Electrocardiogram (ECG).
* Participants with any abnormal laboratory results excluding \[ 25(OH)D, Creatinine (Cr), Calcium (Ca), phosphorus (PO4), C-reactive protein(CRP) , triglyceride , High Density Lipoprotien Cholesterol (HDL-C), Low Density Lipoprotien Cholesterol (LDL-C), total cholesterol (TC)/HDL-C ratio, fasting insulin , fasting blood glucose, oral glucose tolerance test, impaired glucose tolerance, Progesterone, total testosterone, sex hormone binding globulin, parathyroid hormone and free androgen index\].
Healthy Volunteers:
True
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
49 Years
Study:
NCT02328404
Study Brief:
Protocol Section:
NCT02328404